Getinge AB
F:GTN0
Getinge AB
Getinge AB, rooted in the lush landscapes of Sweden, has steadily evolved into a global leader in the medical technology sector. The company began its journey by manufacturing traditional sterilizers over a century ago. Over time, Getinge has carefully navigated and adapted to the ever-changing dynamics of the healthcare industry, positioning itself squarely at the intersection of innovation and practicality. Today, Getinge specializes in a broad spectrum of medical equipment and systems, focusing on critical care, surgery, and infection prevention. This focus is intricately designed to cater to hospitals and healthcare facilities worldwide, ensuring that patients receive the highest standard of care during complex procedures and critical conditions.
Revenue streams for Getinge are as diversified as its product portfolio, comprising equipment sales, service contracts, and consumables. The company’s product offerings range from sophisticated ventilators and state-of-the-art heart-lung machines, to efficient sterilization and surgical workflow products. Beyond simply selling devices, Getinge builds sustainable revenue through long-term service agreements and the sale of replacement parts and consumables, which are essential for the ongoing, optimal operation of its technologically advanced machinery. This strategic emphasis on combining cutting-edge product development with a robust support infrastructure underscores Getinge’s business model, ensuring loyalty and ongoing relationships with healthcare institutions globally.
Getinge AB, rooted in the lush landscapes of Sweden, has steadily evolved into a global leader in the medical technology sector. The company began its journey by manufacturing traditional sterilizers over a century ago. Over time, Getinge has carefully navigated and adapted to the ever-changing dynamics of the healthcare industry, positioning itself squarely at the intersection of innovation and practicality. Today, Getinge specializes in a broad spectrum of medical equipment and systems, focusing on critical care, surgery, and infection prevention. This focus is intricately designed to cater to hospitals and healthcare facilities worldwide, ensuring that patients receive the highest standard of care during complex procedures and critical conditions.
Revenue streams for Getinge are as diversified as its product portfolio, comprising equipment sales, service contracts, and consumables. The company’s product offerings range from sophisticated ventilators and state-of-the-art heart-lung machines, to efficient sterilization and surgical workflow products. Beyond simply selling devices, Getinge builds sustainable revenue through long-term service agreements and the sale of replacement parts and consumables, which are essential for the ongoing, optimal operation of its technologically advanced machinery. This strategic emphasis on combining cutting-edge product development with a robust support infrastructure underscores Getinge’s business model, ensuring loyalty and ongoing relationships with healthcare institutions globally.
Strong Top-Line Growth: Net sales rose 10.7% with 6.2% organic growth, driven mainly by Acute Care Therapies and Americas region.
Improved Margins: Adjusted gross and EBITDA margins improved about 1 percentage point year-on-year, helped by higher volumes, pricing, and mix.
Solid Financial Position: Leverage is stable at 1.4x EBITDA, similar to last year despite acquisitions; management highlights strong balance sheet.
Outlook Unchanged: 2025 guidance for organic net sales growth of 2% to 5% maintained; expectations include some contribution from phased-out businesses and recent acquisitions.
Currency Headwinds: FX negatively impacted Q1 margins by 1.1 percentage points; further currency effect expected to be slightly negative if rates hold.
Life Science Weakness: Life Science segment order intake and sales down, mainly due to funding cuts and project holds in Bio-Processing; mitigating actions underway.
Tariff Uncertainty: Tariffs now in place but too early for financial impact guidance; majority of US sales are produced and sourced domestically.
